EquitySector - HealthcareVery High Risk
Regular
NAV (22-Aug-25)
Returns (Since Inception)
Fund Size
₹3,190 Cr
Expense Ratio
1.91%
ISIN
INF740KA1LD8
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
30 Nov 2018
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+3.51%
+4.67% (Cat Avg.)
3 Years
+25.66%
+24.25% (Cat Avg.)
5 Years
+18.81%
+18.68% (Cat Avg.)
Since Inception
+22.99%
— (Cat Avg.)
Equity | ₹3,131.52 Cr | 98.16% |
Others | ₹58.63 Cr | 1.84% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Cipla Ltd | Equity | ₹278.35 Cr | 8.73% |
Sun Pharmaceuticals Industries Ltd | Equity | ₹262.08 Cr | 8.22% |
Ipca Laboratories Ltd | Equity | ₹250.03 Cr | 7.84% |
Cohance Lifesciences Ltd | Equity | ₹248.57 Cr | 7.79% |
Laurus Labs Ltd | Equity | ₹193.92 Cr | 6.08% |
Gland Pharma Ltd | Equity | ₹190.1 Cr | 5.96% |
Apollo Hospitals Enterprise Ltd | Equity | ₹146.04 Cr | 4.58% |
Illumina Inc | Equity | ₹144.25 Cr | 4.52% |
Alembic Pharmaceuticals Ltd | Equity | ₹139.66 Cr | 4.38% |
Sai Life Sciences Ltd | Equity | ₹137.68 Cr | 4.32% |
Globus Medical Inc Class A | Equity | ₹123.87 Cr | 3.88% |
Pfizer Ltd | Equity | ₹104.22 Cr | 3.27% |
Kovai Medical Center & Hospital Ltd | Equity | ₹103.18 Cr | 3.23% |
Indoco Remedies Ltd | Equity | ₹102.78 Cr | 3.22% |
Vijaya Diagnostic Centre Ltd | Equity | ₹100.57 Cr | 3.15% |
Procter & Gamble Health Ltd | Equity | ₹93.91 Cr | 2.94% |
Concord Biotech Ltd | Equity | ₹86.56 Cr | 2.71% |
Intuitive Surgical Inc | Equity | ₹79.06 Cr | 2.48% |
Treps / Reverse Repo Investments | Cash - Repurchase Agreement | ₹60.53 Cr | 1.90% |
Emcure Pharmaceuticals Ltd | Equity | ₹55.44 Cr | 1.74% |
Unichem Laboratories Ltd | Equity | ₹53.12 Cr | 1.67% |
ICICI Lombard General Insurance Co Ltd | Equity | ₹46.52 Cr | 1.46% |
Aarti Drugs Ltd | Equity | ₹43.18 Cr | 1.35% |
Abbott Laboratories | Equity | ₹34.91 Cr | 1.09% |
Thyrocare Technologies Ltd | Equity | ₹30.37 Cr | 0.95% |
Alkem Laboratories Ltd | Equity | ₹18.78 Cr | 0.59% |
Global X Genomics & Biotechnology ETF | Mutual Fund - ETF | ₹18.6 Cr | 0.58% |
Medplus Health Services Ltd | Equity | ₹17.87 Cr | 0.56% |
Jupiter Life Line Hospitals Ltd | Equity | ₹13.46 Cr | 0.42% |
Laxmi Dental Ltd | Equity | ₹11.83 Cr | 0.37% |
GRAIL Inc | Equity | ₹2.62 Cr | 0.08% |
Net Receivables/Payables | Cash | ₹-1.92 Cr | 0.06% |
Large Cap Stocks
21.52%
Mid Cap Stocks
15.96%
Small Cap Stocks
48.04%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹3,066.42 Cr | 96.12% |
Financial Services | ₹46.52 Cr | 1.46% |
Standard Deviation
This fund
14.38%
Cat. avg.
15.60%
Lower the better
Sharpe Ratio
This fund
1.18
Cat. avg.
1.09
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.99
Higher the better
Since December 2020
ISIN INF740KA1LD8 | Expense Ratio 1.91% | Exit Load No Charges | Fund Size ₹3,190 Cr | Age 6 years 8 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Total AUM
₹2,04,042 Cr
Address
West Wing, 11th Floor, Mumbai, 400021
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Regular
NAV (22-Aug-25)
Returns (Since Inception)
Fund Size
₹3,190 Cr
Expense Ratio
1.91%
ISIN
INF740KA1LD8
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
30 Nov 2018
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+3.51%
+4.67% (Cat Avg.)
3 Years
+25.66%
+24.25% (Cat Avg.)
5 Years
+18.81%
+18.68% (Cat Avg.)
Since Inception
+22.99%
— (Cat Avg.)
Equity | ₹3,131.52 Cr | 98.16% |
Others | ₹58.63 Cr | 1.84% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Cipla Ltd | Equity | ₹278.35 Cr | 8.73% |
Sun Pharmaceuticals Industries Ltd | Equity | ₹262.08 Cr | 8.22% |
Ipca Laboratories Ltd | Equity | ₹250.03 Cr | 7.84% |
Cohance Lifesciences Ltd | Equity | ₹248.57 Cr | 7.79% |
Laurus Labs Ltd | Equity | ₹193.92 Cr | 6.08% |
Gland Pharma Ltd | Equity | ₹190.1 Cr | 5.96% |
Apollo Hospitals Enterprise Ltd | Equity | ₹146.04 Cr | 4.58% |
Illumina Inc | Equity | ₹144.25 Cr | 4.52% |
Alembic Pharmaceuticals Ltd | Equity | ₹139.66 Cr | 4.38% |
Sai Life Sciences Ltd | Equity | ₹137.68 Cr | 4.32% |
Globus Medical Inc Class A | Equity | ₹123.87 Cr | 3.88% |
Pfizer Ltd | Equity | ₹104.22 Cr | 3.27% |
Kovai Medical Center & Hospital Ltd | Equity | ₹103.18 Cr | 3.23% |
Indoco Remedies Ltd | Equity | ₹102.78 Cr | 3.22% |
Vijaya Diagnostic Centre Ltd | Equity | ₹100.57 Cr | 3.15% |
Procter & Gamble Health Ltd | Equity | ₹93.91 Cr | 2.94% |
Concord Biotech Ltd | Equity | ₹86.56 Cr | 2.71% |
Intuitive Surgical Inc | Equity | ₹79.06 Cr | 2.48% |
Treps / Reverse Repo Investments | Cash - Repurchase Agreement | ₹60.53 Cr | 1.90% |
Emcure Pharmaceuticals Ltd | Equity | ₹55.44 Cr | 1.74% |
Unichem Laboratories Ltd | Equity | ₹53.12 Cr | 1.67% |
ICICI Lombard General Insurance Co Ltd | Equity | ₹46.52 Cr | 1.46% |
Aarti Drugs Ltd | Equity | ₹43.18 Cr | 1.35% |
Abbott Laboratories | Equity | ₹34.91 Cr | 1.09% |
Thyrocare Technologies Ltd | Equity | ₹30.37 Cr | 0.95% |
Alkem Laboratories Ltd | Equity | ₹18.78 Cr | 0.59% |
Global X Genomics & Biotechnology ETF | Mutual Fund - ETF | ₹18.6 Cr | 0.58% |
Medplus Health Services Ltd | Equity | ₹17.87 Cr | 0.56% |
Jupiter Life Line Hospitals Ltd | Equity | ₹13.46 Cr | 0.42% |
Laxmi Dental Ltd | Equity | ₹11.83 Cr | 0.37% |
GRAIL Inc | Equity | ₹2.62 Cr | 0.08% |
Net Receivables/Payables | Cash | ₹-1.92 Cr | 0.06% |
Large Cap Stocks
21.52%
Mid Cap Stocks
15.96%
Small Cap Stocks
48.04%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹3,066.42 Cr | 96.12% |
Financial Services | ₹46.52 Cr | 1.46% |
Standard Deviation
This fund
14.38%
Cat. avg.
15.60%
Lower the better
Sharpe Ratio
This fund
1.18
Cat. avg.
1.09
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.99
Higher the better
Since December 2020
ISIN INF740KA1LD8 | Expense Ratio 1.91% | Exit Load No Charges | Fund Size ₹3,190 Cr | Age 6 years 8 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Total AUM
₹2,04,042 Cr
Address
West Wing, 11th Floor, Mumbai, 400021
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments